International recommendations on the diagnosis and treatment of acquired hemophilia A

Andreas Tiede, Peter Collins, Paul Knoebl, Jerome Teitel, Craig Kessler, Midori Shima, Giovanni Di Minno, Roseline d’Oiron, Peter Salaj, Victor Jiménez-Yuste, Angela Huth-Kühne, and Paul Giangrande

Disclosures: AT has received consultancy, lecture fees or research grants from Alnylam, Bayer, Biogen Idec, Biotest, Chugai, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Roche, Shire, and SOBI. PC has received consultancy, lecture fees for research grants from Bayer, Biogen Idec, Chugai, CSL Behring, Novo Nordisk, Roche and Sobi. PK has received consultancy, lecture fees or research grants from Biotest, CSL Behring, Novo Nordisk, Roche, Shire/Takeda. JT has received consultancy, lecture fees, or research support from Bayer, Takeda, Pfizer, Novo Nordisk, Roche, Octapharma, and Bioverativ. CK has served on advisory boards for Bayer, Novo Nordisk, Octapharma, Pfizer, Takeda, and Genentech and has received research funding from Bayer, NovoNordisk, Octapharma, Takeda, and Genentech. He serves on DSMBs for Bayer, Dimensions, Octapharma, and the National Institutes of Health. MS has received consultancy and lecture fees and research grants from Shire, Bayer, Novo Nordisk, CSL Behring, Bioverativ, Chugai. GDM has received honoraria for scientific activities from Bayer, Novo Nordisk, Pfizer, Kedrion, CSL Behring and Sanofi. RdO has received reimbursement for attending symposia/congresses and/or honoraria for lectures or consultancy fees from Bayer, Baxter/Baxalta/Shire, LFB, NovoNordisk, CSL Behring, Octapharma, Pfizer, Roche, Sobi and Spark. PS has received lecture fees from Novo Nordisk and Shire/Takeda. VJY has received reimbursement for attending symposia/congresses and/or honoraria for speaking and/or honoraria for consulting, and/or funds for research from Shire, Bayer, CSL-Behring, Grifols, Novo Nordisk, Sobi, Roche, Octapharma and Pfizer. AHK has received reimbursement for attending symposia/congresses and/or honoraria for speaking and/or honoraria for consulting from Shire, Bayer, CSL-Behring, Novo Nordisk, Sobi and Octapharma. PG has received consultancy and lecture fees received from Bayer, CSL Behring, Novo Nordisk and Pfizer.
Contributions: An update of the 2009 international recommendations on acquired hemophilia A by Huth-Kühne et al had already been discussed by the authors of the original paper in 2009 and was pursued by the lead author (AT), who approached Novo Nordisk Health Care AG, Zurich, Switzerland, with a request to provide editorial support. An initial author meeting attended by AT, PG, CK, JT and Novo Nordisk took place to discuss the project. Novo Nordisk had no further involvement in the development of the manuscript thereafter. The initial author group subsequently invited additional authors based on their country of origin and recognized expertise in the field of AHA management. PG chaired the group discussions and supervised the project. AT wrote a first draft of the manuscript that was subsequently critically revised by all authors. All authors had full access to all of the literature described, contributed to the intellectual development and writing of the manuscript, and take responsibility for the integrity of the data, as well as the accuracy of the data analysis. The final version was approved by all authors.